Thymosin α1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study

  • Authors:
    • Yong‑Rong Liang
    • Zhe Guo
    • Jing‑Hang Jiang
    • Bang‑De Xiang
    • Le‑Qun Li
  • View Affiliations

  • Published online on: September 12, 2016     https://doi.org/10.3892/ol.2016.5121
  • Pages: 3513-3518
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The clinical efficacy of thymosin α1 (Tα1) therapy in patients with hepatocellular carcinoma (HCC) subsequent to radical hepatectomy is unclear. In the present study, the impact of Tα1 therapy on outcomes in HCC patients after radical hepatectomy was retrospectively evaluated. Medical records were retrospectively reviewed for 146 patients with hepatitis B virus (HBV)-associated HCC who were treated by radical hepatectomy and subsequently with Tα1 therapy, as well as for 412 control patients with HBV‑associated HCC treated by radical hepatectomy. Propensity score matching was used to minimize confounding variables due to baseline differences. Liver function, recurrence‑free survival and overall survival rates were compared between the two groups. Serum markers of liver function were significantly improved in the Tα1 group compared with the control group. The 1‑, 2‑ and 3‑year overall survival rates were 87.2, 82.0 and 68.4% in the Tα1 group and 78.2, 64.2 and 49.7% in the control group (P=0.011). The 1‑, 2‑ and 3‑year recurrence‑free survival rates were 79.7, 70.8 and 67.3% in the Tα1 group and 69.9, 61.5 and 51.6% in the control group (P=0.019). The results suggested that post‑hepatectomy Tα1 therapy improves liver function and significantly prolong recurrence‑free and overall survival in patients with HBV‑associated HCC.
View Figures
View References

Related Articles

Journal Cover

November-2016
Volume 12 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liang YR, Guo Z, Jiang JH, Xiang BD and Li LQ: Thymosin α1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study. Oncol Lett 12: 3513-3518, 2016
APA
Liang, Y., Guo, Z., Jiang, J., Xiang, B., & Li, L. (2016). Thymosin α1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study. Oncology Letters, 12, 3513-3518. https://doi.org/10.3892/ol.2016.5121
MLA
Liang, Y., Guo, Z., Jiang, J., Xiang, B., Li, L."Thymosin α1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study". Oncology Letters 12.5 (2016): 3513-3518.
Chicago
Liang, Y., Guo, Z., Jiang, J., Xiang, B., Li, L."Thymosin α1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study". Oncology Letters 12, no. 5 (2016): 3513-3518. https://doi.org/10.3892/ol.2016.5121